Background: Although recent guidelines call for expanded routine screening for HIV, resources for antiretroviral therapy (ART) are limited, and all eligible persons are not currently receiving treatment.
A pproximately 56 000 persons in the United States acquire HIV annually. This number has not decreased in recent years and highlights the need for expanded HIV screening and treatment (1, 2) . Routine HIV screening facilitates early identification of HIV infection, linking infected persons with access to life-saving treatments. If accompanied by an effective counseling program, HIV screening may reduce sexual activity and other risky behavior among participants (3) (4) (5) (6) (7) . Once identified, persons infected with HIV who are eligible to receive antiretroviral therapy (ART) can benefit from substantially reduced mortality and improved quality of life. Moreover, suppressive ART may reduce overall HIV transmission in the population by reducing a recipient's blood plasma viral load and subsequent infectivity (8 -14) .
The Centers for Disease Control and Prevention (CDC) estimates that 21% of the approximately 1.1 million persons living with HIV in the United States are unaware of their disease status, implying that expanded screening could directly benefit almost 250 000 persons and their partners (15). In 2006, the CDC published revised guidelines calling for routine HIV screening in all health care settings of patients aged 13 to 64 years, regardless of potential risk behaviors, unless HIV prevalence is less than 0.1% among patients with undiagnosed HIV (3) . Many other professional organizations have endorsed this policy (16) , and the American College of Physicians recently advised routine screening of patients (17) .
Previous studies have demonstrated that HIV screening is cost-effective. Older analyses focused on specific high-risk groups (18, 19) or settings with a relatively high prevalence (20) . Because ART therapy is now much more effective than it was early in the epidemic, more recent studies show that HIV screening is cost-effective, even in low-prevalence settings in which HIV prevalence exceeds 0.1% to 0.2% (21-25), in patients older than 55 years (26) , and with either conventional or rapid testing (24, 27 ). These studies demonstrate that the cost-effectiveness of screening is critically dependent on the availability of ART. Despite the 2009 U.S. Department of Health and Human Services guidelines recommending ART initiation in patients with CD4 counts from 0.350 to 0.500 ϫ 10 9 cells/L (28), universal ART utilization has not been fully realized. From 2007 to 2009, the CDC's Expanded Testing Initiative resulted in 10 000 persons with newly diagnosed HIV, linking 75% to care (29). However, among persons with newly diagnosed HIV, 36% develop AIDS within 1 year, and 45% develop AIDS within 3 years (30), suggesting that many persons who are linked to care have advanced HIV disease.
Because neither universal HIV screening nor universal treatment of identified persons has been achieved yet, we evaluated how expanding screening, treatment, or both would affect the HIV epidemic in the United States. Unlike most previous analyses (21, 22, 26, 27), we used a modeling framework that can assess the effect of these programs on the entire U.S. population by tracking HIV transmission among several risk groups and the general population. Our goal was to understand whether the expansion of screening, treatment, or both could substantially diminish the HIV epidemic in the United States and whether allocating resources to screening or treatment was more effective and efficient. We also evaluated the effect of reductions in risk behavior on the epidemic.
METHODS

Study Design
We extended a dynamic HIV epidemic model that we previously developed to estimate the health benefits and costs of expanded HIV screening and ART in the United States (31) . We integrated epidemiologic, clinical, and economic data and calculated population-level outcomes that accrue from varying combinations of the 2 interventions. Our model was calibrated to match empirical estimates of incidence and prevalence (see Supplement, available at www.annals.org). We estimated HIV prevalence, incidence, quality-adjusted life-years (QALYs), and health care costs over a 20-year time horizon by using a societal perspective. Our base-case analysis estimates HIV infections averted and incremental cost-effectiveness ratios (ICERs) associated with implementing each program individually or jointly. Because the effects of HIV screening and treatment with ART on risk behavior and disease transmission are uncertain, we varied each intervention's effectiveness. All costs are in 2009 U.S. dollars, and costs and QALYs were discounted at an annual rate of 3% (32). We programmed the model by using Matlab R2010a (MathWorks, Natick, Massachusetts).
HIV Epidemic Model
Our HIV epidemic model captures HIV transmission and progression in the population (Supplement). We partitioned the adult population aged 15 to 64 years into compartments on the basis of sex, risk behavior (men who have sex with men [MSM], injection drug users, or lowrisk persons), HIV infection status, CD4 cell count if infected, treatment status if infected (receiving or not receiving ART), screening status (identified or unidentified), and male circumcision status.
We included HIV transmission through heterosexual and homosexual contact and through needle sharing associated with injection drug use. Heterosexual contact occurs within risk groups (for example, both partners are low risk or both are injection drug users) and across groups (for example, a female injection drug user with a low-risk male partner or a low-risk female with a MSM partner). We assumed proportional mixing, in which persons with many sexual partners are more likely to select a partner who similarly has many partners. The average annual number of sexual partnerships (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) , average condom use (33, 38 -44) , and transmission probability per partnership (8, (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) for each sexual behavior method was estimated on the basis of published data. The model captures HIV transmission through needle sharing in a similar manner, as a function of the annual number of injections (56 -58) , average needle-sharing rates (41, 44, 57, 59) , and probability of transmission per shared needle (57, 60, 61) . The probability of HIV transmission between 2 persons depends on the infected person's sex, disease status, and treatment status and the uninfected person's sex and circumcision status. Finally, the model accounts for changes in risky behavior due to effective HIV screening and counseling (4, 5, 62, 63) .
On acquiring HIV, persons progress through a set of health states at a rate inversely proportional to the average
Context
The incidence of HIV infections in the United States has remained steady over many years.
Contribution
By using a dynamic model, the investigators found that although expanding HIV testing and treatment simultaneously was more beneficial and cost-effective in reducing new infections than using either method alone, new infections only modestly decreased. However, substantial reduction in risk behavior among patients tested and treated would lead to a marked decrease in the number of new infections.
Caution
The model did not include screening for acute HIV infection.
Implication
To substantially decrease the size of the U.S. HIV epidemic, a multimodal approach of testing, treatment, and behavior change would be needed.
-The Editors
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HIV Screening and Treatment
We considered alternative combinations of HIV screening and treatment by varying screening frequency, targeted risk groups, and ART utilization. On the basis of CDC guidelines (3), we considered a strategy offering 1-time screening of low-risk persons, which mostly detects prevalent cases, accompanied by annual screening of highrisk persons, which detects prevalent cases initially and incident cases thereafter. For each strategy, we adjusted the appropriate model measurements to account for changes in sexual behavior and infection transmissibility. We assumed that persons infected with HIV are eligible to initiate ART at a CD4 cell count of 0.350 ϫ 10 9 cells/L, although we also estimated the effect of initiating ART earlier (28) . Persons who receive ART benefit from reduced disease progression and mortality and improved quality of life (21, 64 -67). The partners of infected persons may also benefit because ART suppresses a person's viral load, thus reducing the chance of transmitting the virus. We assumed that ART reduces sexual infectivity by 90% (4, 5, 8, 45, 68 -71) and infectivity related to injection drug use by 50% (21, 56). We varied these measurements widely in the sensitivity analysis.
Before initiating an ART regimen, persons with HIV must first be identified through an HIV screening program or a symptom-based case finding. We assumed a standard rapid HIV testing protocol of an initial enzyme-linked immunosorbent assay followed by a Western blot test to confirm HIV infection. We included the effects of posttest counseling to accompany screening, and we assumed that only persons with HIV reduce their sexual partnerships by 20% (4, 5, 62, 63) but varied this assumption in the sensitivity analysis.
Target Populations
We assessed relevant demographic data for each risk group, including population sizes, HIV prevalence, entry and maturation rates, and mortality rates ( Table 1) . The model was populated using 2007 data, and we numerically solved the dynamic system to estimate population compartment sizes over a 20-year time horizon. Initial HIV prevalence was 12.6% (MSM), 18.8% (MSM injection drug users), 12.9% (male injection drug users), 17.3% (female injection drug users), 0.10% (low-risk men), and 0.22% (low-risk women). Although HIV prevalence varies across geographic regions, we applied a U.S. average to serve as a basis for estimating the benefits of a national HIV screening and treatment campaign.
We estimated that approximately 50% of infected persons receive ART when they have a CD4 cell count less than 0.350 ϫ 10 9 cells/L (29, 30), and thereafter, an additional 5% enter treatment regimens annually, resulting in approximately 85% of eligible persons eventually receiving ART. We calculated an overall prevalence of undiagnosed HIV of 0.11% and an annual incidence rate of 0.03% in our target populations.
Economic Model
We calculated net present health benefits (QALYs) and costs for each strategy. The quality of life for each health state was estimated, and the incremental gain in health benefits due to reduced morbidity and mortality was assessed. We measured lifetime health costs on the basis of HIV disease progression and mortality rates and the associated costs of each health state. Finally, we included the per-person cost of HIV screening and counseling and the annual cost of ART. The ICER for each intervention was calculated relative to the next best alternative.
Role of the Funding Source
The National Institute on Drug Abuse, National Institutes of Health, and Department of Veterans Affairs supported this study. The funding sources had no role in the design, conduct, and reporting of the study or in the decision to submit the manuscript for publication.
RESULTS
HIV Infections Prevented Individual Interventions
Our model projects that approximately 1.23 million new HIV infections will occur over 20 years, with 74% occurring among high-risk persons. Although MSM comprise 4% of adult men, they account for 49% of total new infections, similar to the CDC's estimate of 53% (76).
One-time screening of low-risk persons combined with annual screening of high-risk persons prevents 81 991 infections (6.7% of the projected total), including 23 099 and 58 892 infections among low-risk and high-risk groups, respectively ( Table 2 ). For comparison, targeted annual screening of only MSM could avert 58 513 infections, of which 95% are among MSM; however, the feasibility of risk-based screening is questionable (3) . Routine screening of all persons every 3 years is less effective, preventing 2.3% of infections, because high-risk persons are screened less frequently. A treatment-focused strategy that instead increases ART utilization (at a CD4 cell count Ͻ0.350 ϫ 10 9 cells/L) from 50% to 75% prevents 125 775 infections (10.3% of the total).
Combination Interventions
In general, we found that combination strategies that increase both screening and treatment prevent more HIV infections than the sum prevented from each individual
Original Research Cost-Effectiveness of HIV Screening and Treatment (Figure 1) . A joint strategy that simultaneously offers 1-time screening to low-risk persons and annual screening to high-risk persons and increases ART utilization to 75% prevents 212 291 infections (17.3% of the total). We also examined whether a universal annual HIV screening and treatment with ART (with 90% utilization) could theoretically eliminate the HIV epidemic within the next 2 decades. Such a strategy could prevent 24% of new infections but would not prevent more than 40 000 new infections each year. To substantially reduce HIV incidence, expanded screening and treatment programs must be augmented with programs aimed at reducing risky sexual behavior. Incidence of HIV decreases by 65% if (in addition to universal annual HIV screening and 90% ART utilization) high-risk MSM halve their number of sexual partners and injection drug users halve their needle-sharing frequency. ART ϭ antiretroviral therapy; ELISA ϭ enzyme-linked immunosorbent assay; IDU ϭ injection drug user; MSM ϭ men who have sex with men. * Quality of life for all is multiplied by this quantity.
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False Diagnoses
With annual screening of high-risk persons and 1-time screening of low-risk persons, false-positive and falsenegative diagnoses will occur. We assumed a testing sequence sensitivity of 0.995 and specificity of 0.999994 (21). In the first year of the intervention, approximately 1162 false-positive and 1034 false-negative results occur, but these decrease to 176 and 189 per year, respectively, over 20 years because low-risk persons are screened only once with this strategy. High-risk persons with a falsenegative test result will likely be detected on a future annual screening.
Cost-Effectiveness Analysis
In general, strategies that target screening frequency based on risk status or expand ART are cost-effective (Figure 2 and Table 2 ). One-time screening of low-risk groups and annual screening of high-risk groups add 1.2 million QALYs over 20 years, at a cost of $26.9 billion (discounted) or $22 382 per QALY gained, compared with the status quo. During the first year, this program costs $12.4 billion because of the 1-time screening component. Routine screening every 3 years among all risk groups adds 540 000 QALYs and has an ICER of $112 094 per QALY gained compared with the status quo. This strategy is less effective and more expensive than the former strategy. Annual HIV screening of all adults is less cost-effective at $143 930 per QALY gained.
Alternatively, increasing ART utilization to 75% adds 3.1 million QALYs, with an ICER of $20 300 per QALY gained compared with the status quo. A combination program of 1-time low-risk and annual high-risk screening and 75% ART utilization adds 4.5 million QALYs-more than the sum of implementing each program separatelyat a cost of $92.6 billion over 20 years ($12.9 billion in the ART ϭ antiretroviral therapy; ICER ϭ incremental cost-effectiveness ratio; QALY ϭ quality-adjusted life-year. * Under the status quo, the total number of projected infections over 20 y is given. For the remaining strategies, a negative number refers to infections prevented compared with the status quo. The values in parentheses are the fraction of total HIV infections prevented. Incremental costs and QALYs are relative to the status quo. † The strategy is dominated by another strategy and is not an efficient use of resources.
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Cost-Effectiveness of HIV Screening and Treatment first year) or $21 580 per QALY gained compared with expanded treatment only ( Table 2) .
Sensitivity Analysis
Health outcomes were most sensitive to changes in screening and treatment effectiveness. The effect of viral resistance and other sensitivity analyses are discussed in the Supplement.
Screening Effectiveness
Expanded HIV screening can reduce new infections through 2 mechanisms: infected persons are identified at an earlier stage and can initiate treatment sooner, thereby reducing the chance of infecting their partners, and screened persons may reduce their sexual behavior because of counseling. In the base case, we assumed that both mechanisms are in effect, but only persons with HIV reduce their risky behavior after screening and counseling.
Under these assumptions, 1-time low-risk and annual high-risk screening prevents 6.7% of projected HIV infections. With no reduction in sexual partners after screening, nearly 4% of new infections are still prevented because identified persons initiate ART at an earlier stage ( Figure  3) . This strategy remains cost-effective ($31 615 per QALY gained).
Conversely, a counseling program that successfully reduces partnerships by 50% prevents a significant number of new infections (11.7%) with 1-time low-risk and annual high-risk screening and costs $16 321 per QALY gained.
Under this assumption, universal screening every year costs approximately $100 000 per QALY gained.
ART Effectiveness
We considered variations in the effectiveness of ART at reducing infectivity through sexual transmission. If ART reduces infectivity by 50% instead of 90%, then expanded ART utilization prevents 59 281 infections over 20 years (vs. 125 775 in the base case) and costs $27 585 per QALY gained. With no reduction in sexual infectivity, expanding ART costs $41 367 per QALY gained because of the enormous increase in health benefits from reduced morbidity and mortality among infected persons. The costeffectiveness of expanded treatment improves to $16 000 per QALY gained if ART reduces sexual and needlesharing infectivity completely. Combination screening and treatment cost between $19 000 per QALY and $42 000 per QALY gained if ART is more or less effective, respectively, compared with the next best alternative.
CD4 Cell Count at Initiation of ART
On the basis of recent guidelines recommending earlier treatment of HIV in some patients (28), we considered variations in CD4 cell count at initiation of ART. Because the effect on mortality of ART initiation at a CD4 cell count less than 0.500 ϫ 10 9 cells/L is uncertain, we did exploratory analysis assuming a 50% survival gain with early initiation of ART (91) . If 5% of asymptomatic per- Original Research Cost-Effectiveness of HIV Screening and Treatment sons with HIV enter treatment programs each year, more than twice as many (20.6%) HIV infections are prevented ( Table 2) . Under this scenario, 30% of persons with a CD4 cell count greater than 0.350 ϫ 10 9 cells/L would be receiving ART after 10 years. If 10% of asymptomatic patients begin treatment each year (that is, 50% receive ART after 10 years), 28% of new infections are prevented.
Epidemic Elimination
We assessed whether the HIV epidemic could theoretically be eliminated under the following optimistic assumptions: annual screening of all risk groups, 50% reduction in sexual partners among persons who know they have HIV, 100% ART utilization at CD4 cell count less than 0.350 ϫ 10 9 cells/L, and rapid scale-up of ART for CD4 cell count greater than 0.350 ϫ 10 9 cells/L (60% after 1 year, 80% after 2 years, and 95% after 4 years). This prevents 69% of new infections, but 18 000 infections still occur each year, with more than 60% among injection drug users, largely because ART reduces needle-sharing infectivity only by 50%. If both sexual and needle-sharing infectivity are reduced by 90%, then 9000 infections occur each year. Even with these unrealistic assumptions, it is not possible to eliminate the HIV epidemic in the United States without additional concomitant preventive measures and behavior modification.
Initial HIV Prevalence
In general, as HIV prevalence increases, expanded screening becomes more cost-effective and vice versa. With 50% lower HIV prevalence levels, expanded screening (1-time screening for low-risk persons and annual screening for high-risk persons) costs $31 789 per QALY gained (vs. $22 382 in the base case) but is dominated by expanded ART, which costs $19 829 per QALY gained. Conversely, if HIV prevalence is doubled, both strategies cost less than $22 000 per QALY gained. Screening for HIV is more sensitive to variations in prevalence because of the higher cost of detecting an infected person in a low-prevalence U.S. setting.
DISCUSSION
We aimed to assess the population-wide effects of expanded HIV treatment and screening on the HIV epidemic in the United States. Although previous studies have addressed the effectiveness and cost-effectiveness of either expanded HIV screening (21, 22, 24, 26) or treatment (92-94), they were not designed to fully evaluate how such programs would influence HIV transmission in the overall population or the course of the epidemic. To our knowledge, our study is the first to evaluate the population-wide effects (new HIV infections and other health outcomes) and the cost-effectiveness of alternative combinations of HIV screening and treatment in the United States.
Our study has several key findings. First, we found that expanding HIV screening and treatment could prevent 200 000 to 300 000 infections over 20 years or approximately 17% to 24% of new infections, adding up to 6.8 million QALYs to the population. To prevent 24% of new infections, routine HIV screening would need to occur annually, with antiretroviral treatment available for essentially all symptomatic patients. Our analysis assumes that persons identified as HIV-infected reduce risk behaviors by 20%; even with modest reductions in risk behavior, expansion of screening and treatment would provide enormous health benefits. If persons with HIV reduce risk behavior further, as some studies suggest (7), the health benefit could be substantially higher than we have estimated. Annual HIV screening and counseling leading to 50% behavior reduction in infected persons, along with 90% ART initiation in symptomatic patients, reduces new infections to fewer than 35 000 per year. Even under such optimistic assumptions, the U.S. HIV epidemic is unlikely to be completely eliminated without additional preventive measures.
Second, our analysis highlights the importance of emphasizing risk behavior reduction as HIV screening and treatment becomes increasingly available. For example, in addition to expanded screening and treatment, a 50% reduction in sexual risk behaviors among MSM and needle sharing among injection drug users could prevent 65% of new infections, reducing HIV incidence to approximately 
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Cost-Effectiveness of HIV Screening and Treatment 20 000 cases per year. This suggests that programs to reduce risk behavior among high-risk persons will probably be a key component of a successful prevention program. If, however, uninfected persons increase risk behavior after screening, some of the benefits would be attenuated. Our third finding is that the net benefit of implementing both interventions is greater than the sum from implementing each program individually. A substantial increase in HIV screening or treatment could prevent 95 000 or 198 000 new infections, respectively, whereas a combination program could avert 300 000 infections (an increase of 7000 infections prevented or 2%). Programs to expand screening and treatment will be most effective if they are implemented together, because each program complements the other. Essential to achieving these levels of infections averted is patient receipt of test results after diagnosis, as well as linkage to care, which has been shown to improve with nurse-initiated counseling (95) and health worker follow-up interviews with patients with new diagnoses (96) .
The effectiveness of screening and counseling in reducing sexual activity will probably vary among health care settings because of the differences in risk behavior and the length, content, and intensity of counseling services. Even with no reduction in risk behavior, 1-time screening of low-risk groups and annual screening of high-risk groups could prevent nearly 4% of new infections by identifying infected persons and linking them to treatment programs. Augmenting this strategy with expanded ART prevents 16% of new infections. This suggests that preventing future infections through increased ART becomes increasingly important as the effectiveness of screening and counseling diminishes. In settings in which counseling is unavailable or ineffectual, increased utilization of ART can help ensure that expanded screening will lead to reductions in HIV transmission.
Finally, we find that expanded utilization of ART (to 75% or 90% initiating ART at a CD4 cell count less than 0.350 ϫ 10 9 cells/L) is very cost-effective, as is 1-time screening of low-risk groups and annual screening of highrisk groups. Combination strategies prevent more HIV infections and increase QALYs more than either individual strategy. As noted, our analysis specifically accounts for the effect of combination screening and treatment on population-wide HIV transmission, which is a strength of our modeling framework. As routine HIV screening for adults increases across health care settings due to recently revised CDC guidelines (3), it is important to ensure that ART utilization increases at a concomitant rate. Further expanding HIV screening and counseling services, without expanding the proportion of infected persons receiving ART, does not realize the potential benefits of implementing these 2 complementary interventions.
Compared with other disease screening programs in the United States, 1-time HIV screening of low-risk persons and annual screening of high-risk persons is economically attractive, with a cost-effectiveness ratio less than $23 000 per QALY gained. This compares favorably with other accepted interventions, including screening for type 2 diabetes (97) and breast cancer mammography (98) .
Our study has several limitations. First, we assumed proportional mixing among sexual partners and needlesharing contacts, which simplifies the complex network structure of partnership formation and dissolution. Second, although we stratified the population according to sex and risk behavior, we did not include variations by race or ethnicity. To fully account for such granularity, we would need to accurately estimate sexual and needle-sharing behavior within and between races, which would be difficult to do. Moreover, significant disparities in treatment rates, background mortality, and comorbid conditions exist, and our model cannot account for these additional factors. A third limitation of our study is the omission of acute HIV screening, which would require a different model structure and specific assumptions about the benefits and costs associated with identification and treatment of acute HIV infection. The degree to which acute infection contributes to transmission is uncertain, and estimates vary (47, 99 -103) . Fourth, we used a simplified HIV treatment model that does not include the intricacies of individual HIV disease management; drug toxicities; CD4 cell count monitoring; or the presence of comorbid conditions, such as coronary heart disease, diabetes, and various types of cancer. Our results, however, are broadly consistent with those from more complicated models of HIV disease progression (21-24, 92, 104). Finally, we did not explicitly model development of resistance to ART, although we believe our assumptions about the benefits of ART are conservative given the introduction of new classes of ART, such as integrase inhibitors and entry inhibitors, and we evaluated scenarios that included resistance in sensitivity analyses.
Expanded HIV screening and counseling in the United States can prevent a substantial number of new HIV infections, adding millions of QALYs to the population. Programs that simultaneously expand ART utilization can prevent more HIV infections than expanding either intervention alone. Our analysis indicates that over the next 2 decades, HIV incidence in the United States could be reduced by 24% with a comprehensive expansion of screening and treatment. If these programs are accompanied by additional interventions that halve risky sexual and needle-sharing behavior, the epidemic could be reduced by 65%, suggesting the need for a comprehensive portfolio of HIV prevention, screening, and treatment. 
